Who are Conventional orlistat 120 mg,'s main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Orlistat (Xenical), Xenical, Pegasys, Copegus, sibutramine, orlistat, diethylpropion, Liraglutide + Orlistat, liraglutide combined with orlistat.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/conventional-orlistat-120-mg.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

Conventional orlistat 120 mg, — Competitive Intelligence Brief

Conventional orlistat 120 mg, (Conventional orlistat 120 mg,) competitive landscape: 5 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Lipase inhibitor. Area: Obesity.

phase 2 Lipase inhibitor Pancreatic lipase Obesity Small molecule Live · refreshed every 30 min

Target snapshot

Conventional orlistat 120 mg, (Conventional orlistat 120 mg,) — Empros Pharma AB. Inhibits pancreatic lipase to reduce fat absorption

Comparator set (5 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Conventional orlistat 120 mg, TARGET	Conventional orlistat 120 mg,	Empros Pharma AB	phase 2	Lipase inhibitor	Pancreatic lipase
Orlistat (Xenical)	Orlistat (Xenical)	St. Louis University	marketed	Lipase inhibitor	Pancreatic lipase, gastric lipase
Xenical, Pegasys, Copegus	Xenical, Pegasys, Copegus	Brooke Army Medical Center	marketed	Antiviral combination therapy (interferon + nucleoside analog); Lipase inhibitor	Hepatitis C virus NS5B polymerase; pancreatic lipase
sibutramine, orlistat, diethylpropion	sibutramine, orlistat, diethylpropion	Pennington Biomedical Research Center	marketed	Antiobesity agents (combination)	Norepinephrine transporter, serotonin transporter, pancreatic lipase, sympathomimetic amine receptor
Liraglutide + Orlistat	Liraglutide + Orlistat	East Carolina University	marketed	GLP-1 receptor agonist + lipase inhibitor combination	GLP-1 receptor; pancreatic and gastric lipases
liraglutide combined with orlistat	liraglutide combined with orlistat	The Fourth Affiliated Hospital of Zhejiang University School of Medicine	marketed	GLP-1 receptor agonist combined with pancreatic lipase inhibitor	GLP-1 receptor (liraglutide); pancreatic and gastric lipases (orlistat)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Lipase inhibitor class)

Empros Pharma AB · 1 drug in this class
St. Louis University · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Conventional orlistat 120 mg, — Competitive Intelligence Brief. https://druglandscape.com/ci/conventional-orlistat-120-mg. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab